07:41 AM EDT, 10/13/2026 (MT Newswires) -- BioNTech's (22UA.F) mRNA cancer immunotherapy candidate BNT113 failed to show a statistically significant improvement in progression-free survival in the Ahead-Merit phase 2/3 clinical trial, according to a Tuesday release. The Germany-listed pharmaceutical group is assessing the drug candidate in combination with pembrolizumab against pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent or metastatic human papillomavirus 16-positive head and neck squamous cell carcinoma expressing PD-L1. The trial will continue to evaluate the second dual primary endpoint of overall survival as recommended by the Independent Data Monitoring Committee. Under the trial's predefined statistical design, a statistically significant improvement in overall survival would establish a positive trial outcome even though the progression-free survival endpoint was not met, the company said.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.